RIA
Beyond's analysis on RIA
- — West Pine 43 LLC poised to secure a record valuation multiple amid robust wealth‑management M&A activity
- — UBS expands its RIA platform with $3.5bn acquisition of San Francisco-based Beacon Coast
Recent news mentioning RIA
- — Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study
- — C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
- — Robo.ai Announces Groundbreaking for Phase I of ALIF Holding Group Industrial Park
- — Comviva nomme Jeet Singh à la tête de la croissance mondiale, de la transformation et des partenariats stratégiques
- — MERCURIA AND EXERGY ENERGY SIGN US$250 MILLION INVESTMENT DEAL TO ACCELERATE AFRICAN POWER PROJECTS
- — In Calabria, Sardegna e Sicilia i primi treni a idrogeno a scartamento ridotto al mondo
- — Fastsættelse af rentekuponer for variabelt forrentede obligationer (EUR)
- — Solaria reacciona en el Ibex tras desinflarse un 12% en dos días
- — Bybit svela "Make Your Move" come nuova campagna globale per la nuova piattaforma finanziaria
- — Nucléaire : la construction des six EPR 2 n’a pas encore commencé que les collectivités territoriales s’activent déjà pour accueillir huit autres réacteurs
- — Milei acusa a Sánchez de "traicionar a su propio pueblo" por su política migratoria
- — Avacta Group plc: The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer